By Charlie Johnson, CEO of ADC Bio, adcbio.com Link to full article The scale of patient demand has fuelled an overarching healthcare market need to expand the drug development pipeline to generate more biologics to treat multiple diseases and innovative new biopharmaceuticals to further enhance the treatment of cancer. The effectiveness of antibody drug conjugates and […]
Link to full article Scientist.com is a B2B marketplace that’s transforming scientific research by connecting buyers and sellers of research services for over a decade. Through this exchange, they can deliver faster science through an innovative approach to R&D and find the best resources to support studies in more than 3,000 areas.
Link to full article Posted on March 25, 2019 Value Proposition of Integrated ADC Manufacturing Processes – Use of Economic Modelling-Poster will be presented at PEGS Boston 2019 , April 8-12. Abstract Development and manufacture of biologic-drug conjugates involves a complex supply chain of multiple, different specialised contracted cGMP facilities. CDMOs have simplified project & contractual arrangements either […]
Value Proposition of Integrated ADC Manufacturing Processes – Use of Economic Modelling-Poster will be presented at 9th Annual World ADC. Abstract Development and manufacture of biologic-drug conjugates involves a complex supply chain of multiple, different specialised contracted cGMP facilities. CDMOs have simplified project & contractual arrangements either by forming supplier collaborations or by acquiring specialised facilities […]
Charlie Johnson, CEO of biotechnology company ADC Bio, explains how substantial cost savings and faster time to market is achievable through the novel concept of combining the bioconjugation and purification steps. Charlie Johnson – CEO, ADC Bio As an advanced manufacturing concept, integrated bioconjugation is highly promising – and is now under development – with the […]
Posted on November 14, 2018 ADC Biotechnology (ADC Bio), announces that it has secured additional funding of £2.5 million from existing investors and company management. The investment syndicate consists of Maven Capital Partners, Seneca Partners, the Development Bank of Wales and Downing LLP. The finance will be deployed to ensure the achievement of specific business goals […]
Investment from Downing FOUR VCT (Healthcare and General share classes) advised by BioScience Managers Limited Funds used to progress development of Antibody Drug Conjugate (ADCs) technology Downing FOUR VCT is targeting dividends of at least 4% p.a. (of net assets) from the fourth year onwards * London, UK, 24 April 2018 – London-based investment management […]